Granted I am a newbie biotech investor so...is it normal for a federal agency to request data from a biotech before they get a chance to do a topline report? I know the data is "blinded" however, I don't know that the agency did the same for anyone else in this pandemic. Is it possible the FDA firewall statistician from the interim might have squeaked a little to the top brass?
I know we've talked about the FDA request as nauseum but it just feels like they wouldn't treat this special unless they knew something.